{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:18Z","timestamp":1791920838906,"version":"4.3.4"},"reference-count":44,"publisher":"Informa UK Limited","issue":"18","funder":[{"name":"funded by the National Institute of Health","award":["DA042374"],"award-info":[{"award-number":["DA042374"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.1080\/14656566.2023.2294918","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:34:45Z","timestamp":1704198885000},"page":"1949-1956","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV"],"prefix":"10.1080","volume":"24","author":[{"given":"Jessica","family":"Doan","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, Tennessee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Brunzo-Hager","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, Tennessee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Satterly","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, Tennessee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore James","family":"Cory","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy","place":["Memphis, Tennessee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006841"},{"key":"e_1_3_5_4_1","unstructured":"HIV who.int: World Health Organization. 2023 [cited 2023 sep 4]. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids#:~:text=Globally%2C%2039.0%20million%20%5B33.1\u2013 considerably%20between%20countries%20and%20regions."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.18356\/9789210055475"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.06.001"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707233170401"},{"key":"e_1_3_5_8_1","unstructured":"FDA Approves New HIV Drug for Adults with Limited Treatment Options [Internet]. FDA.gov: FDA. [updated 2022 Dec 22] [cited 2023 Sep 4]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-hiv-drug-adults-limited-treatment-options#:~:text=Sunlenca%20is%20the%20first%20of approved%20for%20treating%20HIV%2D1."},{"key":"e_1_3_5_9_1","volume-title":"Sulenca (R) [package insert] Gilead Sciences","year":"2022","unstructured":"Sulenca (R) [package insert] Gilead Sciences. Foster City CA: Inc; 2022."},{"key":"e_1_3_5_10_1","unstructured":"Study to compare bictegravir\/lenacapavir versus current therapy in people with hiv-1 who are successfully treated with a complicated regimen."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00914-1"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000583"},{"key":"e_1_3_5_13_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department Of Health And Human Services. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf."},{"key":"e_1_3_5_14_1","unstructured":"Global HIV treatment Market analysis Report 2023: a $25+ Billion Market by 2030 - Focus on combination therapies Gaining Momentum - ResearchAndMarkets.com 2023 [cited 2023 Sep 29]. Available from: https:\/\/www.businesswire.com\/news\/home\/20230629675173\/en\/Global-HIV-Treatment-Market-Analysis-Report-2023-A-25-Billion-Market-by-2030\u2014Focus-on-Combination-Therapies-Gaining-Momentum\u2014ResearchAndMarkets.com"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7212e1"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20"},{"key":"e_1_3_5_17_1","volume-title":"Biktarvy (R) [package insert] Gilead Sciences","year":"2022","unstructured":"Biktarvy (R) [package insert] Gilead Sciences. Foster City CA: Inc; 2022."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_5_19_1","unstructured":"Sunlenca: European Unions Agencies Network; 2023 [updated 2023 Jun 27; cited 2023 Aug 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sunlenca"},{"issue":"1","key":"e_1_3_5_20_1","first-page":"A74","article-title":"P176 clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir","volume":"93","author":"Zhang H","year":"2017","unstructured":"Zhang H, Custodio J, Wei X, et al. P176 clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Sex Transm Infect. 2017;93(Suppl 1):A74\u2013A74.","journal-title":"Sex Transm Infect"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00898-8"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001306"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01786-0"},{"key":"e_1_3_5_24_1","unstructured":"Study to evaluate safety pharmacokinetics and antiviral activity of bictegravir (GS-9883) in human immunodeficiency virus (HIV)-1 infected participants."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00291-0"},{"key":"e_1_3_5_27_1","volume-title":"Long-acting Lenacapavir in a combination regimen for treatment naive PWH: week 80 CROI","author":"Hagins D","year":"2023","unstructured":"Hagins D, Safran R, Santiago L, et al., editors. Long-acting Lenacapavir in a combination regimen for treatment naive PWH: week 80 CROI. Seattle WA; 2023."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_5_29_1","volume-title":"Research CfDEa","author":"Center for Drug evaluation and Research","year":"2015","unstructured":"Center for Drug evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. In Research CfDEa. Silver Spring MD: HHS; 2015."},{"key":"e_1_3_5_30_1","unstructured":"Study to Compare Bictegravir\/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Clinicaltrials.gov: NIH National Library of Medicine 2022 [cited 2023 Oct 9]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/record\/NCT05502341?view=record"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb4808"},{"key":"e_1_3_5_32_1","unstructured":"Study of Lenacapavir for HIV pre-exposure prophylaxis in people who are at risk for HIV infection (PURPOSE 2) Clinicaltrials.Gov2022. [cited 2023 Jan 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04925752"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2023.2169207"},{"key":"#cr-split#-e_1_3_5_34_1.1","unstructured":"Biktarvy [Website]. European medicines Agency: European Union agencies network. 2023 [updated 2023 Apr 28"},{"key":"#cr-split#-e_1_3_5_34_1.2","unstructured":"cited 2023 Aug 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/biktarvy#authorisation-details-section"},{"key":"e_1_3_5_35_1","unstructured":"Study to compare bictegravir\/Lenacapavir versus Current therapy in people with HIV-1 who are successfully treated with a complicated regimen [updated January]. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05502341"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2008.0141"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.106"},{"issue":"4","key":"e_1_3_5_38_1","first-page":"675","article-title":"Managing issues related to antiretroviral therapy","volume":"68","author":"Lesho EP","year":"2003","unstructured":"Lesho EP, Gey DC. Managing issues related to antiretroviral therapy. Am Fam Physician. 2003;68(4):675\u2013687.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12421"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02057\u201320"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/11633630-000000000-00000"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570162X15666171120110145"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020933772"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2294918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:05:23Z","timestamp":1744689923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2294918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":44,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,12,12]]}},"alternative-id":["10.1080\/14656566.2023.2294918"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2294918","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}